Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first in human Phase 1a/b clinical study assessing VTX-0811

Next Previous
X
Search
Trial Profile

A first in human Phase 1a/b clinical study assessing VTX-0811

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VTX-0811 (Primary) ; Programmed cell death 1 receptor modulators
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Verseau Therapeutics

    • Most Recent Events

    • 04 Jan 2022 According to Verseau Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for VTX-0811.The FDA has completed its 30-day safety review and granted approval for the company to proceed with this trial. Company expected to initiate this trial in Q1 2022.
    • 13 Sep 2021 New trial record
    • 07 Sep 2021 According to Verseau Therapeutics media release, the company anticipates first-in-human dosing of lead program, VTX-0811, over the coming months.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top